A systematic review and meta-analysis of five randomized controlled trials reports that emerging oral PCSK9 inhibitors reduced LDL cholesterol by an average of 58.37% versus placebo. The analysis also found safety profiles comparable to inactive treatment across included studies. The magnitude of LDL lowering positions the candidates as potential challengers to injectable PCSK9 monoclonal antibodies and supports continued exploration of adherence-driven outcomes in real-world settings. The study frames the evidence as pooled across trials, which can help estimate effect size while acknowledging heterogeneity. For lipid management, oral options could reshape payer and guideline discussions—particularly for patients who struggle with injection access or persistence.
Get the Daily Brief